Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. director Peter C. Farrell reported receiving a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.3000 per share and expire on June 5, 2036.

The filing describes this as the 2026 annual grant for his service on the Board of Directors. According to the footnote, the shares underlying the option vest monthly over a one-year period from the grant date. After this grant, Farrell holds options for 15,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FARRELL PETER C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 15,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 15,000 shares Exercise price: $7.3000 per share Expiration date: June 5, 2036

3 metrics

Option grant size 15,000 shares Stock options underlying common stock granted to director

Exercise price $7.3000 per share Exercise price of stock option grant

Expiration date June 5, 2036 Option expiration for director grant

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, Board of Directors

3 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Board of Directors financial

"2026 annual grant to the Reporting Person as a member of the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

C/O ARCTURUS THERAPEUTICS HOLDINGS INC.

10285 SCIENCE CENTER DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$7.3	06/05/2026		A		15,000		(1)	06/05/2036	Common Stock	15,000	$0.00	15,000	D

Explanation of Responses:

1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.

	/s/ Ilan Katz, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arcturus Therapeutics (ARCT) disclose about Peter C. Farrell in this Form 4?

Arcturus Therapeutics reported that director Peter C. Farrell received a grant of stock options for 15,000 shares. These options are compensation for his Board service and give him the right to buy common stock at a fixed exercise price.

How many Arcturus Therapeutics (ARCT) options did Peter C. Farrell receive?

Peter C. Farrell received stock options covering 15,000 shares of Arcturus Therapeutics common stock. The filing shows this entire 15,000-share option position as held directly following the transaction, representing his reported derivative holdings from this grant.

What is the exercise price and expiration date of Peter C. Farrell’s ARCT options?

The stock options granted to Peter C. Farrell have an exercise price of $7.3000 per share and expire on June 5, 2036. He can choose to exercise the options at that price before the expiration date, subject to vesting.

How do Peter C. Farrell’s Arcturus (ARCT) options vest?

The options granted to Peter C. Farrell vest monthly over a one-year period from the grant date. This means portions of the 15,000-share award become exercisable each month during that first year, aligning with ongoing Board service.

Is Peter C. Farrell’s ARCT Form 4 transaction an open-market stock purchase?

No. The Form 4 shows a stock option grant coded as a grant, award, or other acquisition, not an open-market purchase. It reflects equity-based compensation, giving Farrell the right to buy shares later at a set price.